| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Financial Officer
4 companies
Newton Charles W. serves as a Director at CHRS and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 1 buy and 5 sells. Those positions are worth an estimated $286K at current prices.
Historically, Newton Charles W.'s trades have earned a below-average insider score of 44/100 across 5 rated trades. Over a 12-month horizon, 25.0% of those trades were profitable, with an average 12-month return of -6.4%.
The biggest single holding is LYEL (~$161K) as Chief Financial Officer. Net of sales, the recent Form 4 record there shows accumulation of 198,280 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | KROS Keros Therapeutics, Inc. | Director | Sell10b5-1 | 551 | $10.30 | $5,675.30 | -4.4% | - | - | |
| Jun 11, 2026 | KROS Keros Therapeutics, Inc. | Director | Sell10b5-1 | 550 | $10.04 | $5,522.00 | -4.2% | +12.5% | - | |
| Aug 21, 2025 | LYEL Lyell Immunopharma, Inc. | Chief Financial Officer | Sell | 1,453 | $10.54 | $15,320.43 | -8.7% | +61.7% | +45.8% | |
| Aug 12, 2025 | LYEL Lyell Immunopharma, Inc. | Chief Financial Officer | Sell | 267 | $10.43 | $2,784.87 | -3.0% | +67.3% | +34.1% | |
| Mar 17, 2025 | LYEL Lyell Immunopharma, Inc. | Chief Financial Officer | Buy | 200,000 | $0.56 | $111,620.00 | New | -1.7% | +94.7% |